Completed Phase I Clinical Study of 4-1BB Based Anti-CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia; Achieved 90% Complete […]
Boston, MA, July 13, 2020 (GLOBE NEWSWIRE) — According to a recent article from The Hechinger Report*, during school closures, many educators trusted […]
ARQ-252 is a potent and highly selective topical JAK1 inhibitor offering potential safety advantages over less selective JAK inhibitorsCompany expects […]
SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation […]